Intuitive Sets Pace In A Robotics Segment Where Ortho Players Are Finding Their Feet

For hospitals, orthopedic capabilities might seem like an arms race – they do not want to be left behind the curve when rivals are tooling up. Patients may have positive views of the technology, even if data on clinical benefits is not yet available in great volumes. So says Jefferies Healthcare equity analyst Raj Denhoy, who believes it is not a done deal for health care robotics just yet.        

Intuitive Surgical Inc. and its da Vinci technology have blazed a trial for robotic-assisted minimally-invasive surgery in five surgical specialties (gynecologic surgery, urologic surgery, general surgery, cardiothoracic surgery, and head and neck surgery) since the first US FDA approval in 2000. The group is the global technology leader, with 4,528 installed locations as of the end of the second quarter in 2018, and a fast-growing reputation in key procedures such as prostatectomy, hernia repair, colon and rectal procedures.

Orthopedics is not on that list, but all of the major orthopedic groups look set to have robotic capabilities, at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By 

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By 

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.